Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023752%3A_____%2F22%3A43920875" target="_blank" >RIV/00023752:_____/22:43920875 - isvavai.cz</a>

Result on the web

<a href="https://journals.sagepub.com/doi/10.1177/02698811211050556" target="_blank" >https://journals.sagepub.com/doi/10.1177/02698811211050556</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1177/02698811211050556" target="_blank" >10.1177/02698811211050556</a>

Result language

angličtina

Original language name

Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study

Original language description

Background: Microdoses of psychedelics (i.e. a sub-hallucinogenic dose taken every third day) can reduce symptoms of depression, anxiety and stress according to anecdotal reports and observational studies. Research with medium to high doses of psilocybin points towards potential underlying mechanisms, including the modulation of emotion and interoceptive processing. Aims: In this preregistered study, we investigated whether psilocybin microdoses alter self-reported interoceptive awareness and whether repeated microdosing over 3 weeks modulates emotion processing and reduces symptoms of anxiety and depression. Methods: We used a double-blind, placebo-controlled, within-subject crossover design. Participants completed the Multidimensional Assessment of Interoceptive Awareness Questionnaire 11/2 h after self-administering their second dose (or placebo), and the emotional go/no-go task and the shortened Depression Anxiety Stress Scale 11/2 h after self-administering their seventh dose. Results: Our confirmatory analyses revealed that psilocybin microdosing did not affect emotion processing or symptoms of anxiety and depression compared with placebo. Our exploratory analyses revealed that psilocybin microdosing did not affect self-reported interoceptive awareness, that symptoms of depression and stress were significantly reduced in the first block compared with baseline, that participants broke blind in the second block and that there was no effect of expectations. Further research in a substance-naive population with clinical range anxiety and depressive symptoms is needed to substantiate the potential beneficial effects of microdosing.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30210 - Clinical neurology

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2022

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Journal of Psychopharmacology

ISSN

0269-8811

e-ISSN

1461-7285

Volume of the periodical

36

Issue of the periodical within the volume

1

Country of publishing house

GB - UNITED KINGDOM

Number of pages

17

Pages from-to

97-113

UT code for WoS article

000731590000001

EID of the result in the Scopus database

2-s2.0-85121519345